BioCentury This Week

BioCentury Podcasts
  • 3.3 (3)
  • LIFE SCIENCES
  • UPDATED WEEKLY
BioCentury This Week

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

  1. Ep. 277 - Asia's NewCo Model, FDA Tipping Point, Vertex's Pain Drug

    4 DAYS AGO

    Ep. 277 - Asia's NewCo Model, FDA Tipping Point, Vertex's Pain Drug

    The boom in the creation of companies that were launched in the West based on assets sourced in Asia signals China’s galloping speed of innovation. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the “NewCo Model,” who the players are, from CEOs and companies to investors; the areas of innovation the start-ups are tackling; and the evolution of the trend. (Read about the company that kicked off the trend, Arrivent, here.) The editors also assess how personnel losses a...

    25 min
  2. Ep. 276 - Precision Neuropsychiatry Spotlight With ICON's Peter Schueler

    31 JAN

    Ep. 276 - Precision Neuropsychiatry Spotlight With ICON's Peter Schueler

    Psychiatric drug development has had major wins over the past year-and-a-half — think Karuna Pharmaceuticals' $14 billion takeout by Bristol Myers Squibb and the subsequent launch of a new schizophrenia therapy — but targeted neuropsychiatric drug development is still in its infancy. On a special edition of the BioCentury This Week podcast, BioCentury’s editors detail the promise of precision medicine in the space and break down what recent setbacks for key players mean for next steps in the ...

    21 min
  3. Ep. 275 - Series As & Innovation. Plus: Rocky Transition at FDA, NIH

    28 JAN

    Ep. 275 - Series As & Innovation. Plus: Rocky Transition at FDA, NIH

    BioCentury’s analysis of the technologies behind last year’s biotech series A raisers sees progress in nanoparticles, CAR cell therapies, degraders and antibody-drug conjugates. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the trends spotted in 2024’s crop of more than 150 series A rounds — from top therapeutic areas and modalities to the leading investors funding the innovation.The editors turn to Washington for takeaways from BioCentury’s “exit interview” with Pa...

    33 min
  4. Ep. 274 - 2025 Biotech Preview: Markets, Catalysts and AI

    22 JAN

    Ep. 274 - 2025 Biotech Preview: Markets, Catalysts and AI

    With political uncertainty overshadowing market sentiment going into 2025, BioCentury’s editorial team assesses the bull and bear arguments for biotech in the New Year on the BioCentury This Week podcast’s Public Markets Preview. Will continued uncertainty drive biotech sentiment in the coming months, or will the bear arguments fail to manifest, stymied by M&A and other positive factors? In the second part of the 2025 Preview, BioCentury’s editors highlight some of the key catalysts in bi...

    36 min
  5. Ep. 273 - JPM 2025 Wrap: Sunny Skies & Megarounds

    17 JAN

    Ep. 273 - JPM 2025 Wrap: Sunny Skies & Megarounds

    Sunshine and a stream of deals brightened the mood at this year’s J.P. Morgan Healthcare Conference, offering a pleasant counterpoint to continued pessimism over the state of the capital markets. On the latest BioCentury This Week podcast, BioCentury’s editors deliver their takeaways from biotech’s annual kick-off event from megarounds and Asian newcos to the new state of M&A and pending change at FDA. View full story: https://www.biocentury.com/article/654723 00:00 - Introduction 01:52...

    22 min
  6. Ep. 272 - JPM Deal Buzz & Rep. Auchincloss’ Take on Biopharma

    13 JAN

    Ep. 272 - JPM Deal Buzz & Rep. Auchincloss’ Take on Biopharma

    J&J’s $14.6 billion takeout of neurology play Intra-cellular Therapies headlined a buzzy start to the J.P. Morgan Healthcare Conference, where a flurry of deal announcements recalled the conference’s pre-pandemic days. On the latest BioCentury This Week podcast, BioCentury's editors discuss the takeout of Intra-cellular, the third 11-digit neuro M&A in the past 13 months, as well as M&A involving Idrx and GSK, and Scorpion Therapeutics and Eli Lilly. Turning to Washington, the tea...

    27 min
  7. Ep. 271 - Biotech in the New Year. Plus: Beyond Biosecure

    7 JAN

    Ep. 271 - Biotech in the New Year. Plus: Beyond Biosecure

    Can biotech break free of the macro factors that have buffeted the industry of late? On the first BioCentury This Week podcast of 2025, BioCentury’s editors offer their predictions for the New Year and — exploring the themes from Simone Fishburn’s latest Letter from the Editor — ask whether biotech can overcome the financing environment, policy concerns and geopolitical tension that have been hammering the industry to deliver on the meaningful strides companies have been taking to deliver inn...

    35 min
  8. Ep. 270 - Temple’s FDA Legacy. Plus: Chinese Innovation & Novo Obesity Data

    30/12/2024

    Ep. 270 - Temple’s FDA Legacy. Plus: Chinese Innovation & Novo Obesity Data

    Preview: In his five decades at FDA, Robert “Bob” Temple helped revolutionize the ways medical products are developed and regulated. On the latest BioCentury This Week podcast, Washington Editor Steve Usdin reflects on the legacy of Temple. Temple, who is retiring, crafted the modern clinical trial paradigm, created the accelerated approval pathway, and set precedents for incorporating patient perspectives in regulatory decisions. Usdin also discusses the opportunities and threats for the age...

    35 min
See All (287)

Ratings & Reviews

3.3
out of 5
3 Ratings

About

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

Information

More From BioCentury Podcasts

You Might Also Like

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes and get the latest updates.
Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada